Login / Signup

Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer.

Joris van de HaarJoanne M MankorKarlijn HummelinkKim MonkhorstEgbert F SmitLodewyk F A WesselsEdwin CuppenJoachim G J V AertsEmile E Voest
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The unexpected ICB responses in patients carrying resistance biomarkers in STK11, KEAP1 and EGFR were almost exclusively observed in patients with a high TMB. Considering these alterations in the context the TMB offered a highly specific combinatorial biomarker strategy for limiting overtreatment in NSCLC.
Keyphrases